Yikon Genomics provides NIPT and liquid biopsy tests using next-generation sequencing. Its proprietary MALBAC-NGS platform enables selective amplification of target DNA, with kits for non-invasive prenatal testing, pre-implantation genetic testing, SNP-based tumor profiling, and HER2/BRCA testing, plus liquid biopsy for personalized cancer therapies. Founded in 2012 in Changping District, China, the company has raised $31.3M in Series C funding from investors including 6 Dimensions Capital and Frontline BioVentures. Provider of NIPT and liquid biopsy tests using next-generation sequencing. Its proprietary MALBAC - NGS platform enables selective amplification of target DNA. It currently has kits for non-invasive prenatal testing, pre-implantation genetic testing, SNP-based tumor profiling, HER2 and BRCA testing. In addition, the company also has a liquid biopsy test for enabling targeted personalized cancer therapies.
← All startups
Yikon Genomics
Series CYikon Genomics provides NIPT and liquid biopsy tests using next-generation sequencing. Its proprietary MALBAC-NGS platform enables selective amplification of target DNA, with kits for non-invasive prenatal testing, pre-implantation genetic testing, SNP-based tumor profiling, and HER2/BRCA testing, plus liquid biopsy for personalized cancer therapies. Founded in 2012 in Changping District, China, the company has…
About
Business model
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Portfolio of Sequencing-based Diagnostics
Team background
College Wise > Harvard University
Institutional investors
Guangzhou Yuexiu Industrial Investment Fund ManagementBank of CommunicationsZhongyuan Jiupai FundJinhe Capital6 Dimensions CapitalCash CapitalTMCPFrontline BioVenturesShengshan Capital
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.